Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3175-3178

  Wong, J P ^a   Christopher, M E ^a   Salazar, A M ^b   Dale, R M K ^c   Sun, L Q ^d   Wang, M ^d  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^b Oncovir Inc   (United States)

^c Oligos Etc Inc   (United States)

^d CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Avian influenza; Broad spectrum; Nucleic acid based antiviral drugs

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; DOUBLE STRANDED RNA; MESSENGER RNA; NUCLEIC ACID BASE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; DRUG POTENCY; FEMALE; INFLUENZA VIRUS A; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; VIRUS EXPRESSION; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS STRAIN;

EID: 33947589836     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.051     Document Type: Article

References (11)

1. World Health Organization. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_11_13/en/index.html.
2. Krieg A.M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489 (1999) 107-116
3. Wong J.P., Saravolac E.G., Sabuda D., Levy H.B., and Kende M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother 39 (1995) 2574-2576
4. Levy H.B., Baer G., Baron S., Buckler C.E., Gibbs C.J., Iadorola M.J., et al. A modified polyriboinosinic-polyribocyticylic acid complex that induces interferon in monkeys. J Infect Dis 132 (1975) 434-439
5. Wong J.P., Yang H., Nagata L., Kende M., Levy H., Schnell G., et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double stranded RNA poly ICLC. Vaccine 17 (1999) 1788-1795
6. Wong J.P., Nagata L.P., Christopher M.E., Salazar A.M., and Dale R.M.K. Prophylaxis of acute respiratory virus infection using nucleic acid-based drugs. Vaccine 23 (2005) 2266-2268
7. Stephen E.L., Sammons M.L., Pannier W.L., Baron S., and Spertzel R.O. Effect of a nuclease-resistant derivative of a polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis 136 (1977) 122-126
8. Kende M. Prophylactic and therapeutic efficacy of poly (I,C)-LC against Rift Valley fever virus infection in mice. J Biol Response Mod 4 (1985) 503-511
9. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
10. Smith G.J., Fan X.H., Wang J., Li K.S., Qin K., Zhang J.X., et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci USA 103 (2006) 16936-16941
11. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., et al. Fatal outcome of human influenza (H5N1) is associated with high virus load and hypercytokinemia. Nat Med 12 (2006) 1203-1207